iShares Core MSCI Europe ETF
IEUR - ETF AI Analysis
Top Page
iShares Core MSCI Europe ETF (IEUR)
IEUR’s rating suggests it is a solid, broadly diversified way to invest in major European companies, with its quality driven by several financially strong leaders. Large positions in firms like Novartis, HSBC, and AstraZeneca support the fund through robust profitability, positive earnings sentiment, and generally reasonable valuations, while holdings such as SAP and Allianz introduce some risk due to bearish technical trends and potential overvaluation. The main risk factor is exposure to individual stocks with short-term technical weakness or valuation concerns, which can add volatility even within this diversified European portfolio.
IEUR vs. SPDR S&P 500 ETF (SPY)
- AUM
- 9.81B
- Region
- Europe
- Expense Ratio
- 0.09%
- Beta
- 0.74
- Issuer
- iShares
- Inception Date
- Jun 10, 2014
- Dividend Yield
- 3.15%
- Asset Class
- Equity
- Index Tracked
- MSCI Europe IMI
IEUR Summary
IEUR is the iShares Core MSCI Europe ETF, a fund that aims to follow the MSCI Europe IMI index, giving you broad exposure to stocks across many European countries and industries. It holds well-known companies like Nestlé, Shell, HSBC, and Novartis, mixing large, established firms with smaller, growing businesses. Someone might invest in IEUR to diversify beyond the U.S. market and tap into long-term growth in Europe with one simple purchase. A key risk is that European stock prices can rise and fall with the overall market and regional economic conditions.
How much will it cost me?
IEUR has an expense ratio of 0.09%, which means you’ll pay about $0.90 per year for every $1,000 invested. This cost is lower than the average ETF because IEUR is a passively managed index fund that simply tracks the MSCI Europe IMI rather than paying managers to pick individual stocks.
What would affect this ETF?
This ETF could benefit if Europe’s economy strengthens, interest rates stabilize or fall, and major sectors like financials, health care, and industrials see steady growth, which would support companies such as ASML, Roche, HSBC, and Shell. On the other hand, a European recession, higher or more volatile interest rates, stricter banking or energy regulations, or political tensions in developed European countries could hurt these sectors and weigh on the fund’s overall performance.
IEUR Top 10 Holdings
IEUR is leaning heavily on Europe’s blue-chip growth and health names, with ASML acting as the main engine: despite some recent choppiness, its strong year-to-date run is a key driver for the fund. Roche and Novartis add steady, rising support from the healthcare side, while SAP’s improving momentum gives the portfolio a tech kicker. On the flip side, HSBC has been lagging lately, and consumer staples like Nestlé plus pharma giant AstraZeneca are losing a bit of steam. Overall, it’s a diversified, developed Europe play, not dominated by any single country.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 NL:ASML | ASML Holding NV | 3.82% | $373.43M | EUR 519.88B | 58.28% | 76Outperform |
 RHHVF | Roche Holding AG | ― | ― | ― | ― | 73Outperform |
 CH:NOVN | Novartis AG | 1.88% | $183.50M | CHF 246.17B | 27.54% | 80Outperform |
 GB:HSBA | HSBC Holdings | 1.98% | $193.71M | GBP 229.76B | 23.30% | 80Outperform |
 GB:SHEL | Shell (UK) | 1.81% | $177.01M | GBP 205.39B | 25.21% | 73Outperform |
 AZN | AstraZeneca | ― | ― | ― | ― | 80Outperform |
 CH:NESN | Nestlé SA | 1.71% | $167.12M | CHF 222.27B | 5.72% | 71Outperform |
 DE:SAP | SAP SE | 1.52% | $148.79M | EUR 245.13B | -2.81% | 66Neutral |
 DE:SIE | Siemens | 1.43% | $140.06M | EUR 206.99B | 11.96% | 74Outperform |
 DE:ALV | Allianz | 1.26% | $123.09M | EUR 172.63B | 29.14% | 67Neutral |
IEUR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IEUR, the sentiment is Positive. The current price of 76.00 is above the 20-day moving average (MA) of 74.55, above the 50-day MA of 74.70, and above the 200-day MA of 73.99, indicating a bullish trend. The MACD of 0.41 indicates Negative momentum. The RSI at 56.90 is Neutral, neither overbought nor oversold. The STOCH value of 85.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IEUR.
IEUR Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| IEUR | $76.00 | $79.00(3.95% Upside) | $9.81B | 0.09% | 63Neutral |
 EZU | $67.83 | $80.19(18.21% Upside) | $9.38B | 0.50% | 63Neutral |
 BBEU | $77.96 | $90.19(15.69% Upside) | $9.24B | 0.09% | 64Neutral |
 FEZ | $67.50 | $80.43(19.16% Upside) | $4.23B | 0.29% | 67Neutral |
 HEDJ | $58.20 | $67.19(15.44% Upside) | $1.79B | 0.58% | 60Neutral |
 IEV | $73.46 | $85.30(16.12% Upside) | $1.60B | 0.60% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IEUR | iShares Core MSCI Europe ETF | 76.00 | 8.51 | 12.60% | |
| EZU | iShares MSCI Eurozone ETF | 67.83 | 6.20 | 10.05% | |
| BBEU | JPMorgan BetaBuilders Europe ETF | 77.96 | 8.58 | 12.37% | |
| FEZ | SPDR EURO STOXX 50 ETF | 67.50 | 5.49 | 8.85% | |
| HEDJ | WisdomTree Europe Hedged Equity Fund | 58.20 | 6.86 | 13.36% | |
| IEV | iShares Europe ETF | 73.46 | 7.92 | 12.09% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.